Drug intelligence / Profile preview

SYHX2005

Development stage: Phase 1
Lead developer: CSPC Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

SYHX2005 is an orally bioavailable, highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). It acts as a type I FGFR4 antagonist and is being developed for its potential antineoplastic (anti-cancer) activity. The drug is designed to block the activity of FGFR4, a receptor implicated in the growth and survival of certain cancer cells. SYHX2005 is currently under investigation in early-phase clinical trials for the treatment of advanced solid tumors[1][2][7].

Targets

FGFR4 (Fibroblast growth factor receptor 4)

Beyond the preview

Go deeper on SYHX2005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYHX2005.

Explore the full profile